{"id":"transdermal-system-containing-progestin","safety":{"commonSideEffects":[{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Skin irritation at patch site"},{"rate":null,"effect":"Irregular bleeding"}]},"_chembl":{"chemblId":"CHEMBL412214","moleculeType":"Small molecule","molecularWeight":"976.97"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Progestins work by suppressing the luteinizing hormone (LH) surge needed for ovulation, thickening cervical mucus to impede sperm transport, and altering the endometrium to prevent implantation. The transdermal formulation provides steady-state hormone delivery over several days, improving compliance and reducing fluctuations compared to oral dosing.","oneSentence":"A transdermal progestin delivery system that releases the hormone through the skin to provide contraceptive and/or hormone replacement effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:45.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Hormone replacement therapy (if applicable to specific formulation)"}]},"trialDetails":[{"nctId":"NCT06672016","phase":"PHASE3","title":"Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential","status":"RECRUITING","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2025-01-13","conditions":"Female Contraception","enrollment":1500},{"nctId":"NCT01623466","phase":"PHASE1, PHASE2","title":"Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2012-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT00377988","phase":"","title":"A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":423},{"nctId":"NCT00331071","phase":"","title":"Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Transdermal system containing progestin","genericName":"Transdermal system containing progestin","companyName":"Mylan Pharmaceuticals Inc","companyId":"mylan-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A transdermal progestin delivery system that releases the hormone through the skin to provide contraceptive and/or hormone replacement effects. Used for Contraception, Hormone replacement therapy (if applicable to specific formulation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}